Stockscreener 앱 받기
0.3596
1.05%
-0.0038
시장 영업 전:
.36
0.0004
+0.11%
전일 마감가:
$0.3634
열려 있는:
$0.36
하루 거래량:
248.14K
Relative Volume:
0.10
시가총액:
$14.07M
수익:
$1.50M
순이익/손실:
$-64.59M
주가수익비율:
-0.2153
EPS:
-1.67
순현금흐름:
$-55.17M
1주 성능:
+5.45%
1개월 성능:
-10.32%
6개월 성능:
-87.93%
1년 성능:
-87.16%
1일 변동 폭
$0.338
$0.3664
1주일 범위
$0.338
$0.38
52주 변동 폭
$0.2223
$4.79
립 테라퓨틱스 Stock (LPTX) Company Profile
명칭
Leap Therapeutics Inc
전화
617 252 4343
주소
47 THORNDIKE STREET, CAMBRIDGE, MA
LPTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
0.3596 | 14.07M | 1.50M | -64.59M | -55.17M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
립 테라퓨틱스 Stock (LPTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-01-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2021-10-04 | 개시 | Mizuho | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2020-06-29 | 개시 | Piper Sandler | Overweight |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2019-11-15 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-09-13 | 재개 | Raymond James | Outperform |
| 2017-03-07 | 개시 | Ladenburg Thalmann | Buy |
모두보기
립 테라퓨틱스 주식(LPTX)의 최신 뉴스
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatam - GuruFocus
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer | LPTX Stock News - GuruFocus
Leading Oncologist Reveals Game-Changing Phase 2 Results for Advanced Colorectal Cancer Treatment - Stock Titan
Leap Therapeutics stock hits 52-week low at $0.28 amid downturn - Investing.com Canada
Leap Therapeutics stock hits 52-week low at $0.28 amid downturn By Investing.com - Investing.com South Africa
HC Wainwright Expects Reduced Earnings for Leap Therapeutics - Defense World
HC Wainwright Reiterates Neutral Rating for Leap Therapeutics (NASDAQ:LPTX) - Defense World
H.C. Wainwright maintains neutral on Leap Therapeutics stock By Investing.com - Investing.com Canada
Leap reports progress in colorectal cancer study By Investing.com - Investing.com South Africa
Driving the Future of Healthcare HIT, OSRH, THTX, LPTX, CSDX, Innovations in Health Insurance, Virtual Care, Oncology, and Chronic Disease Treatment - Financial Content
Micro Cap Soars Following Preliminary Data Update - The Globe and Mail
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - Benzinga
LEAP THERAPEUTICS Earnings Results: $LPTX Reports Quarterly Earnings - Nasdaq
Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial - MarketScreener
Leap Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study - MarketScreener
Leap Therapeutics Reports Positive DeFianCe Phase 2 Data Of Sirexatamab In Colorectal Cancer - Nasdaq
Leap Therapeutics Reports Fourth Quarter And FY 2024 Results - Marketscreener.com
Leap reports progress in colorectal cancer study - Investing.com India
Breakthrough: Leap's Colorectal Cancer Drug Delivers 32% Higher Response Rate in Latest Trial - Stock Titan
Tobacco Control Has Saved Nearly 4 Millions Lives, Study Estimates - 69News WFMZ-TV
Leap Therapeutics stock hits 52-week low at $0.39 - Investing.com
Leap Therapeutics stock hits 52-week low at $0.39 By Investing.com - Investing.com UK
Leap Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
LEAP THERAPEUTICS Earnings Preview: Recent $LPTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Leap Therapeutics stock hits 52-week low at $0.4 amid sharp decline - Investing.com India
Leap Therapeutics stock hits 52-week low at $0.4 amid sharp decline By Investing.com - Investing.com South Africa
Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses - Marketscreener.com
Sun Pharma's Strategic Leap: Acquiring Checkpoint Therapeutics - Devdiscourse
Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma -March 10, 2025 at 06:24 am EDT - Marketscreener.com
Leap Therapeutics (LPTX) to Release Quarterly Earnings on Monday - Defense World
Gastric Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Earnings To Watch: L.B. Foster (FSTR) Reports Q4 Results Tomorrow - The Globe and Mail
PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors - ACCESS Newswire
Nebius Stock Investors Have Reason to Cheer as the Company Expands Rapidly Into AI Infrastructure - The Globe and Mail
Leap Therapeutics stock hits 52-week low at $0.47 amid downturn - Investing.com Canada
Keurig Dr Pepper Earnings: What To Look For From KDP - The Globe and Mail
Amicus Therapeutics’ Bold Leap Toward Billion-Dollar Milestone - Smartphone Magazine
Cathie Wood Keeps Dumping Palantir Stock. Should You? - The Globe and Mail
Got $3,500? Should You Buy Ethereum or XRP (Ripple)? - The Globe and Mail
Biliary Tumor Market Set to Grow Substantially Through 2032, - openPR
Recent Insider Activity Suggests Potential Gains for Vaxart Inc (VXRT) - Knox Daily
Analytical Lens: Exploring Leap Therapeutics Inc (LPTX)’s Financial Story Through Ratios - The Dwinnex
Biliary Tract Cancer Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Agios Pharma, Servier Pharma, Merck Sharp & Dohme, AstraZeneca, Taiho Onco - Barchart
Get in on Leap Therapeutics Inc’s (LPTX) buy-in window today! - SETE News
Leap Therapeutics Inc (LPTX) stock analysis: A simple moving average approach - US Post News
China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment - Yahoo Finance
What is HC Wainwright's Estimate for LPTX FY2029 Earnings? - MarketBeat
Analyzing Leap Therapeutics Inc (NASDAQ: LPTX) Stock’s Performance and Trends for Investment - Marketing Sentinel
Leap Therapeutics (NASDAQ:LPTX) Downgraded by Baird R W to "Hold" - MarketBeat
립 테라퓨틱스 (LPTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):